Sensitivity Factors and Human Pathology Related to Infections of Producing Escherichia Coli of Shiga-Toxin
American Journal of Life Sciences
Volume 5, Issue 3-1, May 2017, Pages: 60-66
Received: Nov. 28, 2016; Accepted: Jan. 11, 2017; Published: Apr. 15, 2017
Views 1592      Downloads 54
Authors
Saїd Oulkheir, High Institute of Nursing Professions and Health Techniques, ISPITS, Agadir, Morocco
Khadija Ounine, Laboratory of Applied Microbiology Department of Biology, Faculty of Sciences, Ibn Tofail University, Kenitra, Morocco
Mohamed Aghrouch, Laboratory of Medical Analysis, Hospital Hassan II, Agadir, Morocco
Smail Chadli, High Institute of Nursing Professions and Health Techniques, ISPITS, Agadir, Morocco
Article Tools
Follow on us
Abstract
Escherichia coli O157: H7 is the main serotype E. coli responsible for disease in humans. STEC strains (Shiga-toxin-producing E. coli) are all strains with genes encoding Stx toxin cytotoxic for Vero cell cultures (kidney cell of African green monkey), hence the name "verotoxin"also called"Shiga toxin"because of its great similarity to a toxin produced by Shigella dysenteriae. Infections caused by EHEC (Enterohemorrhagic E. coli) are a major problem due to the extreme severity of the clinical manifestations they can generate. These translate into a banal or bloody diarrhea may develop in 5-8% of cases, mainly in young children, to a serious complication hemolytic uremic syndrome (HUS) or thrombotic thrombocytopenic purpura (TTP) in adults. The identification of susceptibility factors of clinical interest because it may allow early specific treatment of patients at risk of complications.
Keywords
Enterohemorrhagic E. coli, Factors of Susceptibility, Hemolytic Uremic Syndrome, Shiga-toxin-Producing E. coli, Shigatoxin
To cite this article
Saїd Oulkheir, Khadija Ounine, Mohamed Aghrouch, Smail Chadli, Sensitivity Factors and Human Pathology Related to Infections of Producing Escherichia Coli of Shiga-Toxin, American Journal of Life Sciences. Special Issue: Environmental Toxicology. Vol. 5, No. 3-1, 2017, pp. 60-66. doi: 10.11648/j.ajls.s.2017050301.19
Copyright
Copyright © 2017 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
Caprioli A., Morabito S., Brugere H., Oswald E. Enterohaemorrhagic Escherichia coli : emerging issues on virulence and modes of transmission. Vet. Res. 2005, 36, 289-311.
[2]
Karmali M. A. Infection by verocytotoxin-producing Escherichia coli. Clin. Microbiol. Rev. 1989, 2, 15-38.
[3]
Griffin, P. M., and Tauxe, R. V. The epidemiology of infections caused by Escherichia coli O157:H7, other enterohemorrhagic E. coli, and the associated hemolytic uremic syndrome. Epidemiol Rev. 1991, 13: 60-98.
[4]
Todd, W. T., and Dundas, S. The management of VTEC O157 infection. Int J Food Microbiol 2001, 66: 103-110.
[5]
Wilson, J. B., Clarke, R. C., Renwick, S. A., Rahn, K., Johnson, R. P., Karmali, M.A et al. Vero cytotoxigenic Escherichia coli infection in dairy farm families. J Infect Dis. 1996, 174: 1021-1027.
[6]
Conlan, J. W., and Perry, M. B. Susceptibility of three strains of conventional adult mice to intestinal colonization by an isolate of Escherichia coli O157:H7. Can J Microbiol 1998, 44: 800-805.
[7]
Kurioka, T., Yunou, Y., and Kita, E. Enhancement of susceptibility to Shiga toxin-producing Escherichia coli O157:H7 by protein calorie malnutrition in mice. Infect Immun 1998, 66: 1726-1734.
[8]
Ray, P. E., and Liu, X. H. Pathogenesis of Shiga toxin-induced hemolytic uremic syndrome. Pediatr Nephrol 2001, 16: 823-839.
[9]
Tarr, P. I. Escherichia coli O157: H7: clinical, diagnostic, and epidemiological aspects of human infection. Clin Infect Dis 1995, 20: 1-8; quiz 9-10.
[10]
Sharp, J. C., Ritchie, L. D., Curnow, J., and Reid, T. M. High incidence of haemorrhagic colitis due to Escherichia coli O157 in one Scottish town: clinical and epidemiological features. J Infect 1994, 29: 343-350.
[11]
Su, C., and Brandt, L. J. Escherichia coli O157:H7 infection in humans. Ann Intern Med 1995, 123: 698-714.
[12]
MacDonald, K. L., O'Leary, M. J., Cohen, M. L., Norris, P., Wells, J. G., Noll, E., Kobayashi, J. M., and Blake, P. A. Escherichia coli O157:H7, an emerging gastrointestinal pathogen. Results of a oneyear, prospective, population-based study. Jama 1988,259: 3567-3570.
[13]
Griffin, P. M., Olmstead, L. C., and Petras, R. E. Escherichia coli O157:H7-associated colitis. A clinical and histological study of 11 cases. Gastroenterology 1990, 99: 142-149.
[14]
Kelly, J., Oryshak, A., Wenetsek, M., Grabiec, J., and Handy, S. The colonic pathology of Escherichia coli O157:H7 infection. Am J Surg Pathol 1990, 14: 87-92.
[15]
Keene, W. E., McAnulty, J. M., Hoesly, F. C., Williams, P., Hedberg, K., Oxman, G. L., Barrett, T. J., Pfaller, M. A., and Flezming, D. W. A newly recognised source of Escherichia coli O157: H7 infections. Gastroenterology 1995, 108: 1597-1602.
[16]
Morgan, G. M., Newman, C., Palmer, S. R., Allen, J. B., Shepherd, W., Rampling, A. M., Warren, R. E., Gross, R.J., Scotland, S. M., and Smith, H. R. First recognized community outbreak of haemorrhagic colitis due to verotoxin-producing Escherichia coli O 157: H7 in the UK. Epidemiol Infect 1988, 101: 83-91.
[17]
Waters, J. R., Sharp, J. C., and Dev, V. J. Infection caused by Escherichia coli O157:H7 in Alberta, Canada, and in Scotland: a five-year review, 1987-1991. Clin Infect Dis 1994, 19: 834-843.
[18]
Karmali, M. A., Steele, B. T., Petric, M., and Lim, C. Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools. Lancet 1983, 1: 619-620.
[19]
Loirat, C., Baudouin, V., Sonsino, E., Mariani-Kurkdjian, P., and Elion, J. SyndromeHémolytique et Urémique de l'enfant : aspects cliniques, étiologiques, éléments du pronostic et résultats thérapeutiques. In Actualités Néphrologiques de l'Hopital Necker. Flammarion-Médecine-Sciences (ed). Paris, pp. 133-158, 1992.
[20]
Fong, J. S., de Chadarevian, J. P., and Kaplan, B. S. Hemolytic-uremic syndrome. Current concepts and management. Pediatr Clin North Am 1982, 29: 835-856.
[21]
Loirat, C. Syndrome Hémolytique et Urémique typique post diarrhée: aspects cliniques. Arch Pediatr 8 Suppl. 2001, 4: 776s-784s.
[22]
Siegler, R. L. Spectrum of extrarenal involvement in postdiarrheal hemolytic-uremic syndrome. J Pediatr 1994, 125: 511-518.
[23]
Decludt, B., Bouvet, P., Mariani-Kurkdjian, P., Grimont, F., Grimont, P. A., Hubert, B., Loirat, C., and Pediatrique, and Société de Néphrologie Pédiatrique. Haemolytic uraemic syndrome and Shiga toxin-producing Escherichia coli infection in children in France. Epidemiol Infect 2000, 124: 215-220.
[24]
Repetto, H. A. Epidemic hemolytic-uremic syndrome in children. Kidney Int 1997, 52: 1708-1719.
[25]
Gagnadoux, M. F., Habib, R., Gubler, M. C., Bacri, J. L., and Broyer, M. Long-term (15-25 years) outcome of childhood hemolytic-uremic syndrome. Clin Nephrol 1996, 46: 39-41.
[26]
Huseman, D., Gellermann, J., Vollmer, I., Ohde, I., Devaux, S., Ehrich, J. H., and Filler, G. Long-term prognosis of hemolytic uremic syndrome and effective renal plasma flow. Pediatr Nephrol 1999, 13: 672-677.
[27]
Maroeska, D., Te Loo, D. M., Monnens, L., and al., e. Binding and transfert of verocytotoxin by polymorphonuclear leukocytes in hemolytic uremic syndrome. Blood 2000, 95: 3396-3402.
[28]
Moschcowitz, E. An acute febrile pleochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries. Arch Intern Med 1925, 36: 89.
[29]
Kovacs, M. J., Roddy, J., Gregoire, S., Cameron, W., Eidus, L., and Drouin, J. Thrombotic thrombocytopenic purpura following hemorrhagic colitis due to Escherichia coli O157: H7. Am J Med 1990, 88: 177-179.
[30]
Hofmann, S. L. Southwestern Internal Medicine Conference: Shiga-like toxins in hemolyticuremic syndrome and thrombotic thrombocytopenic purpura. Am J Med Sci 1993, 306: 398-406.
[31]
Miedouge, M., Hacini, J., Grimont, F., and Watine, J. Shiga toxin-producing Escherichia coli urinary tract infection associated with hemolytic-uremic syndrome in an adult and possible adverse effect of ofloxacin therapy. Clin Infect Dis 2000, 30: 395-396.
[32]
Starr, M., Bennett-Wood, V., Bigham, A. K., de Koning-Ward, T. F., Bordun, A. M., Lightfoot, D., Bettelheim, K. A., Jones, C. L., and Robins-Browne, R.M. Hemolytic-uremic syndrome following urinary tract infection with enterohemorrhagic Escherichia coli : case report and review. Clin Infect Dis 1998, 27: 310-315.
[33]
Ludwig, K., Petric, M., Blanchette, V., and Karmali, M. Isolated thrombocytopenic purpura associated with infection due to verocytotoxin (Shiga toxin)-producing Escherichia coli serotype O26: H11. Clin Infect Dis 1998, 27: 660-661.
[34]
Cimolai, N., Carter, J. E., Morrison, B. J., and Anderson, J. D. Risk factors for the progression of Escherichia coli O157: H7 enteritis to hemolytic-uremic syndrome. J Pediatr 1990, 116: 589-592.
[35]
Kim, H. H., Samadpour, M., Grimm, L., Clausen, C. R., Besser, T. E., Baylor, M., Kobayashi, J. M., Neill, M. A., Schoenknecht, F. D., and Tarr, P. I. Characteristics of antibiotic-resistant Escherichia coli O157:H7 in Washington State, 1984-1991. J Infect Dis 1994, 170: 1606-1609.
[36]
Wong, C. S., Jelacic, S., Habeeb, R. L., Watkins, S. L., and Tarr, P. I. The risk of the hemolyticuremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med 2000, 342: 1930-1936.
[37]
Vermeyen, H. M., Karch, H., Brandis, M., and Zimmerrhackl, L. B. Enterohemmorrhagic Escherichia coli Infections : following transmission routes. Pediatr Nephrol 14: 73-83.
[38]
Igarashi, T. [Treatment in initial stage of VTEC infection]. Nippon Rinsho 2000, 2002, 60: 1121-1125.
[39]
Gyles, C. Vaccines and Shiga Toxines-producing Escherichia coli in animals. In Escherichia coli O157:H7 ond Other Shiga Toxines-producing Escherichia coli strains. Kaper, J. and O'Brien, A. D. (eds). Washington D. C.: ASM Press, pp. 434-444, 1998.
[40]
Nataro, J. P., and Kaper, J. B. Diarrheagenic Escherichia coli. Clin Microbiol Rev 1998, 11: 142-201.
[41]
Paton, A. W., and Paton, J. C. Direct detection of Shiga toxigenic Escherichia coli strains belonging to serogroups O111, O157, and O113 by multiplex PCR. J Clin Microbiol 1999, 37: 3362-3365.
[42]
Tauxe, R. V. Public Health perspective on immunoprophylactic strategies for Escherichia coli O157:H7: Who or What would we immunize? In Escherichia coli O157:H7 ond Other Shiga Toxinesproducing Escherichia coli strains. Kaper, J. and O'Brien, A. D. (eds). Washington D. C.: ASM Press, pp. 445-452, 1998.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186